Answers are grounded in this paper and cite their sources.
Systematic review identifies low-cost predictors of Alzheimer's disease progression in individuals with mild cognitive impairment, suggesting improved risk assessment.
Background Mild Cognitive Impairment represents a transitional stage between normal cognitive ageing and Alzheimer’s Disease. Although numerous predictors of progression have been investigated, many rely on costly or specialized investigations that remain readily inaccessible in routine clinical practice. This systematic review aimed to identify and synthesize evidence on low cost clinical predictors of progression of mild cognitive impairment to Alzheimer’s Disease that are readily available. Methods A systematic literature search of PubMed was conducted to identify longitudinal studies evaluating predictors of progression of mild cognitive impairment to Alzheimer’s Disease. Studies were screened according to predefined eligibility criteria, data was extracted using a standard approach, and methodological quality was assessed using the Newcastle Ottawa Scale. Due to the heterogeneity in study designs and outcome measures, a qualitative synthesis was conducted. Results Twenty-six longitudinal studies met the inclusion criteria. Neuropsychological measures, particularly episodic memory performance and recall, emerged as the most consistent predictors of progression. Neuropsychiatric symptoms, vascular and metabolic characteristics, sensory and functional measures, routine laboratory biomarkers, electrophysiological assessments, and multivariable clinical prediction models also demonstrated varied degrees of prognostic values. Overall, combining multiple accessible clinical predictors appeared to improve risk stratification compared to reliance to individual predictors. Conclusions Low cost clinical predictors provide meaningful prognostic information for identifying individuals with mild cognitive impairment at increased risk of progression to Alzheimer’s disease. Integrating these accessible predictors into routine into clinical assessment may facilitate earlier risk stratification, particularly in resource limited settings where advanced biomarkers are unavailable. Further prospective validation is required to develop standardized, multivariable prediction models suitable for widespread clinical implementation.
No takes yet. Share an insight, caveat, or question.
bryan Moyo (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: